EUVIMEDEUVIMED entdecken
Crossref

Repurposing the Antihypertensive Agent Hydralazine As an Inhibitor of the Base Excision Repair Enzyme APE1

Tanhaul Islam, Venkatrao Nunna, Don Pivithuru Liyanarachchi iD, Douglas Melton, Calvin D Lewis, Kent S Gates iD

Chemical Research in Toxicology · 2025

DOI: 10.1021/acs.chemrestox.4c00445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Research in Toxicology, 2025. Verfasst von Tanhaul Islam und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Missouri, Department of Chemistry, 125 Chemistry Building, Columbia, Missouri 65211, United States. Hauptthemen laut MEDLINE: Hydralazine, DNA-(Apurinic or Apyrimidinic Site) Lyase, Antihypertensive Agents, DNA Repair. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: NIEHS NIH HHS, National Institute of Environmental Health Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Apurinic/apyrimidinic endonuclease 1 (APE1) is a central enzyme in the base excision repair (BER) pathway. APE1 catalyzes incision of the phosphodiester linkage on the 5'-side of apurinic/apyrimidinic (AP) sites during the repair of damaged nucleobases in cellular DNA. Inhibition of this enzyme can potentiate the action of DNA-damaging chemotherapeutic agents. The antihypertensive drug hydralazine generates covalent AP adducts that block the catalytic action of APE1. Hydralazine was found to be superior to the investigational drug methoxyamine in its capacity to covalently capture AP sites in duplex DNA and inhibit the action of APE1. It was further shown that hydralazine sensitized SF295 glioblastoma cells to the cytotoxic action of the anticancer drug Temozolomide, which generates alkylpurine residues requiring APE1 for repair. The results suggest that the FDA-approved drug hydralazine might be repurposed in oncology to potentiate the activity of existing chemotherapeutic agents that induce AP sites in cellular DNA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydralazineDNA-(Apurinic or Apyrimidinic Site) LyaseAntihypertensive AgentsDNA RepairDrug RepositioningEnzyme InhibitorsHumansCell Line, TumorAntineoplastic AgentsMolecular StructureTemozolomideExcision RepairHydroxylamines

Substanzen

HydralazineDNA-(Apurinic or Apyrimidinic Site) LyaseAntihypertensive AgentsAPEX1 protein, humanEnzyme InhibitorsmethoxyamineAntineoplastic AgentsTemozolomideHydroxylamines

Autor:innen und Institutionen

  • University of Missouri, Department of Chemistry, 125 Chemistry Building, Columbia, Missouri 65211, United States.
  • Washington University School of Medicine Department of Radiation Oncology, Box 8224, 4921 Parkview Place, St. Louis, Missouri 63110, United States.
  • University of Missouri, Department of Biochemistry, 125 Chemistry Building, Columbia, Missouri 65211, United States.

ORCID-Profile: Don Pivithuru Liyanarachchi, Kent S Gates

Förderung

  • NIEHS NIH HHS
  • National Institute of Environmental Health Sciences

Zitieren

APA

Islam, T., Nunna, V., Liyanarachchi, D. P., Melton, D., Lewis, C. D., & Gates, K. S. (2025). Repurposing the Antihypertensive Agent Hydralazine As an Inhibitor of the Base Excision Repair Enzyme APE1. Chemical Research in Toxicology. https://doi.org/10.1021/acs.chemrestox.4c00445

Vancouver

Islam T, Nunna V, Liyanarachchi DP, Melton D, Lewis CD, Gates KS. Repurposing the Antihypertensive Agent Hydralazine As an Inhibitor of the Base Excision Repair Enzyme APE1. Chemical Research in Toxicology. 2025. doi:10.1021/acs.chemrestox.4c00445

BibTeX
@article{Islam2025,
  author = {Islam, Tanhaul and Nunna, Venkatrao and Liyanarachchi, Don Pivithuru and Melton, Douglas and Lewis, Calvin D and Gates, Kent S},
  title = {Repurposing the Antihypertensive Agent Hydralazine As an Inhibitor of the Base Excision Repair Enzyme APE1},
  journal = {Chemical Research in Toxicology},
  year = {2025},
  doi = {10.1021/acs.chemrestox.4c00445}
}
Kostenlos starten →